"It's an Approved Drug in Russia." That's the Weakest Argument for Semax, Not the Strongest.

"It's an approved drug in Russia." That line usually ends the conversation. It should start one.

I sell Semax. Our listing says it is "a synthetic heptapeptide analog of ACTH(4-10) studied in nootropic and neurotrophic research models," it prints ≥99% purity, and it ships with a certificate of analysis that confirms identity by LC-MS and prints the mass-confirmation spectra. All of that is true and none of it tells you whether the compound does anything. A COA is a receipt, not a result. So when a customer asks me the honest version of the question, which is where does the Semax research actually come from, I don't get to answer with a purity number.

Here is the part that surprised me when I went looking. Semax's problem is not that the evidence is thin. It's that the evidence is deep in one place and absent almost everywhere else, and the claims people repeat come from the place with nothing in it.

Quick vocabulary, then I'll leave it alone. A heptapeptide is seven amino acids strung together. ACTH is adrenocorticotropic hormone, the pituitary hormone that runs your stress-hormone schedule. Semax is a modified copy of a short fragment of it. "Analog" just means modified copy.

Three layers, and the loudest one is empty

Think of Semax's evidence as three layers. The first is clinical: human patients, overwhelmingly from one national research tradition. The second is preclinical: rodents, published in places you can read. The third is inferred: forum posts, product pages, screenshots, nobody's data at all. Each layer supports a different sentence. The sentence most buyers repeat comes from layer three.

I can't hand you layer one. I went looking for something I could put in front of you line by line, and what I kept finding was the clinical work referenced rather than the clinical work readable: patients with neurological problems, not healthy people trying to write better email. I'm not going to summarise sample sizes and effect sizes I could not verify myself, and I'm not going to launder "registered in Russia" into "proven." Registration is a procedural fact about a dossier in a regulator's filing cabinet. I have never read that dossier. Neither has the person quoting it at you. That cuts both ways: it is not evidence of efficacy by Western standards and it is not evidence of fraud, and anyone telling you the Russian literature is junk because it's Russian is doing nationality, not methodology. The real criticisms available are about transparency, indexing, independence, and replication.

Layer two I can hand you, and it's genuinely interesting. In transgenic mice engineered to carry human Alzheimer's mutations, Semax and a derivative improved performance on cognitive tasks: open field, novel object recognition, and the Barnes maze, which is a table full of holes where you measure whether the mouse remembers which hole is the escape. Histology showed fewer amyloid inclusions, the protein clumps that define the model, in the cortex and hippocampus. The authors' own conclusion was that these are candidates for further research into corrective strategies. Not "it works." Candidates.

Now the same layer, less flattering. In the rodent Parkinson's-like models that have been reviewed, Semax given on its own did not significantly change striatal dopamine or improve locomotor activity. In one study, Semax given 20 minutes before d-amphetamine markedly amplified the amphetamine's dopamine release and the movement that went with it, while Semax alone produced no change in dopamine at all. Read that twice. The compound's most dramatic dopamine result in that literature required a stimulant to be in the room. And in humans with Parkinson's disease, per that same review, no clinical trials have tested its efficacy. Zero.

On anxiety-related outcomes, nearly all the rodent studies included in that review found improvement. In rodents, "anxiety-related outcome" means how long a mouse spends in the exposed part of a maze. It does not mean a person felt calmer.

Somewhere in this same body of work is a study of Semax and Selank in rats with experimental thermal burns, where burn exposure raised total leukocyte count, neutrophil phagocytic activity and band-form leukocytes, and the peptides were reported to contribute to correcting those white-cell changes. Which is not what anybody had in mind when they typed "nootropic" into a search bar.

Run the same test on Selank, which I also sell

The framework only counts if I apply it to my own shelf. Selank's mechanistic rodent data is a good stress test. Intranasal Selank in mice reduced glycine binding sites at the NMDA receptor in the cortex by 18% in one strain, BALB/c, and by 53% in another, C57Bl/6. Given by injection into the abdomen instead, the hippocampus numbers went the other way: 11% down in BALB/c, 45% down in C57Bl/6. In BALB/c mice, intranasal Selank increased hippocampal binding sites by 15%, while in C57Bl/6 nothing tested moved that number.

Same compound. Two mouse strains. Threefold disagreement.

If the answer changes that much between two inbred mouse lines, the honest position on what it does in your skull is that nobody has measured it. That is not a knock on the work. That is what the work says.

So here is your tool, and it costs nothing to use. For any claim about any compound, ask three questions: which population was this measured in, which species, and has anyone outside the originating research group ever repeated it? For Semax, the answers are neurological patients, often rodents, and largely no. That is a real evidence base. It is not the one that supports what most people bought it for.